Clover Health to Participate in Upcoming Investor Conferences
29 Ottobre 2024 - 9:05PM
Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover
Health” or the “Company”), today announced its participation in the
following investor conferences:
- CFO, Peter Kuipers, will present at the 2024 UBS Global
Healthcare Conference on Tuesday, November 12, 2024, at 5:00 p.m.
Eastern Time.
- CFO, Peter Kuipers, will participate in the Canaccord Genuity
2024 Medical Technology, Diagnostics, and Digital Health &
Services Forum on Thursday, November 21, 2024.
- CEO, Andrew Toy, will participate in the Virtual BTIG Digital
Health Forum on Monday, November 25, 2024.
- CFO, Peter Kuipers, will present at the 2024 Citi Global
Healthcare Conference on Tuesday, December 3, 2024, at 3:15 p.m.
Eastern Time.
A live webcast and reply of the fireside chat presentations will
be accessible from Clover Health's investor relations website at
https://investors.cloverhealth.com/.
About Clover Health:Clover Health (Nasdaq:
CLOV) is a physician enablement technology company committed to
bringing access to great healthcare to everyone on Medicare. This
includes a health equity-based focus on seniors who have
historically lacked access to affordable, high-quality healthcare.
Our strategy is powered by our software platform, Clover Assistant,
which is designed to aggregate patient data from across the
healthcare ecosystem to support clinical decision-making and
improve health outcomes through the early identification and
management of chronic disease. For our members, we provide PPO and
HMO Medicare Advantage plans in several states, with a
differentiated focus on our flagship wide-network, high-choice PPO
plans. For healthcare providers outside Clover Health's Medicare
Advantage plan, we aim to extend the benefits of our data-driven
technology platform to a wider audience via our subsidiary,
Counterpart Health, and to enable enhanced patient outcomes and
reduced healthcare costs on a nationwide scale. Clover Health has
published data demonstrating the technology’s impact on Medication
Adherence, as well as the earlier identification and management of
Diabetes and Chronic Kidney Disease.
Press Contact:Andrew
Still-Baxterpress@cloverhealth.com
Investor Relations Contact:Ryan
Schmidtinvestors@cloverhealth.com
Grafico Azioni Clover Health Investments (NASDAQ:CLOV)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Clover Health Investments (NASDAQ:CLOV)
Storico
Da Dic 2023 a Dic 2024